Literature DB >> 10975813

CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation.

J G Chai1, S Vendetti, E Amofah, J Dyson, R Lechler.   

Abstract

Two apparently contradictory observations have been made concerning peripheral T cell tolerance; costimulation-deficient Ag presentation leads to unresponsiveness, and CTLA4 (CD152) ligation is required for unresponsiveness to be induced. This issue was addressed using a CD80- CD86low B cell line to present Ag to DO.11.10 naive CD4+ T cells. Proliferation was substantially enhanced by anti-CD80 or anti-CD152, but was inhibited by anti-CD86. Furthermore, anti-CD80 partially, and anti-CD152 totally protected cloned DO.11.10 T cells from the induction of unresponsiveness following culture with peptide and Chinese hamster ovary H2-Ad+ CD80- CD86- cells. Fab of anti-CD80 caused similar enhancement, and coimmobilized anti-CD80 failed to costimulate the anti-CD3 response of purified T cells, indicating that direct signaling by anti-CD80 was not responsible for these effects. The possibility that anti-CD80 liberated CD28 molecules that were sequestered by the T cell-expressed CD80, enabling them to coaggregate with TCR:CD3 complexes was excluded by finding that anti-CD80 and anti-CD152 individually caused maximal enhancement, rather than having additive effects. These data suggest that T cell-expressed CD80 has a regulatory function and plays a key role in the induction of unresponsiveness due to costimulation-deficient Ag presentation by the ligation of CD152 on neighboring, or even the same, T cell.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975813     DOI: 10.4049/jimmunol.165.6.3037

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Long-term control of alloreactive B cell responses by the suppression of T cell help.

Authors:  Yijin Li; Lianli Ma; Dengping Yin; JiKun Shen; Anita S Chong
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

2.  Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell.

Authors:  James E D Thaventhiran; Anja Hoffmann; Lukasz Magiera; Maike de la Roche; Holger Lingel; Monika Brunner-Weinzierl; Douglas T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-27       Impact factor: 11.205

3.  CD4+ CD25+ regulatory T cells suppress CD4+ T-cell function and inhibit the development of Plasmodium berghei-specific TH1 responses involved in cerebral malaria pathogenesis.

Authors:  Catherine Q Nie; Nicholas J Bernard; Louis Schofield; Diana S Hansen
Journal:  Infect Immun       Date:  2007-02-26       Impact factor: 3.441

4.  Activation of T cell checkpoint pathways during β-cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes.

Authors:  Radhika R Gudi; Nicolas Perez; Subha Karumuthil-Melethil; Gongbo Li; Chenthamarakshan Vasu
Journal:  Immunology       Date:  2022-04-22       Impact factor: 7.215

5.  Expression of class I MHC molecule, HSP70 and TAP in human hepatocellular carcinoma.

Authors:  Xiao-Ling Deng; Wei Chen; Mei-Ying Cai; Da-Peng Wei
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

6.  Administration of exogenous interleukin-18 and interleukin-12 prevents the induction of oral tolerance.

Authors:  Alfred D Eaton; Damo Xu; Paul Garside
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

7.  Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands.

Authors:  Li-Te Chin; Chishih Chu; Han-Min Chen; Shu-Ching Hsu; Bor-Chun Weng; Chi-Hong Chu
Journal:  BMC Biotechnol       Date:  2007-08-23       Impact factor: 2.563

8.  Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions.

Authors:  Andreas O Doesch; Li Zhao; Christian A Gleissner; Mohammadreza Akhavanpoor; David Rohde; Deniz Okuyucu; Maani Hakimi; Thomas J Dengler; Hugo A Katus; Christian Erbel
Journal:  Drug Des Devel Ther       Date:  2014-05-12       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.